FLASH radiation therapy could introduce a transformative approach by delivering lightning-quick cancer therapy at ultra-high dose rates.

While conventional radiotherapy typically requires daily sessions over several weeks, FLASH involves far fewer treatment sessions, with each lasting less than a second. A clinical trial underway at Penn Medicine is exploring the “conformal,” or precise 3D targeting, version of FLASH for the first time in human patients in the United States.

“Radiation therapy impacts patients’ lives in ways that are hard to appreciate,” said principal investigator Alexander Lin, MD. “We want to be able to offer a treatment with minimal toxicity that’s easy and convenient so that patients can spend more time with family and friends.”